GRIPHON

May 17, 2016May 25, 2016

Actelion’s Uptravi for PAH Granted Marketing Authorization by European Commission

The European Commission recently granted marketing authorization in the EU for Switzerland-based Actelion’s product Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. PAH is a life-threatening disease characterized by abnormal constriction of the pulmonary ... Read more

March 24, 2016March 24, 2016

Actelion’s PAH Therapy, Uptravi (selexipag), Approved for Use in Australia and New Zealand

News, Pulmonary Hypertension

Actelion, Ltd., recently announced the approval of Uptravi (selexipag) by the Therapeutic Goods Administration (TGA) of Australia and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) for the treatment ... Read more

February 2, 2016February 3, 2016

European Medicines Agency Gives Positive Opinion to Uptravi for Long-Term PAH Treatment

News, Pulmonary Hypertension

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has given a positive opinion to Uptravi (selexipag) for the treatment of pulmonary ... Read more

October 23, 2015November 5, 2015

New PAH Trial Results for Selexipag Therapy to Be Presented by Actelion at CHEST 2015

News, Pulmonary Hypertension

Actelion, Ltd., a biopharmaceutical company headquartered in Switzerland and focused on the discovery, development, and commercialization of innovative treatments for unmet medical needs, recently announced that additional important results from its pivotal Phase ... Read more

September 24, 2015November 5, 2015

Clinical Trial Data On PH Therapy Selexipag (Uptravi) & Macitentan (Opsumit) To Be Presented At European Respiratory Society Congress

News, Pulmonary Hypertension

Actelion BioPharmaceuticals recently announced that the company will be releasing important data from its Phase III GRIPHON study testing the efficacy and tolerability of their pipeline drug selexipag (Uptravi®) for the treatment ... Read more

August 27, 2015November 5, 2015

Actelion to Present Data on Selexipag (Uptravi) and Macitentan (Opsumit) for PAH at Upcoming European Conference

News, Pulmonary Hypertension

Actelion Ltd, a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs, recently announced that the results of its ... Read more

March 23, 2015November 5, 2015

Long-term Data on Selexipag for PAH Presented at American College of Cardiology (ACC) 2015

News, Pulmonary Hypertension

Actelion Ltd recently presented long-term results at the American College of Cardiology (ACC) Congress in San Diego, US from their pivotal selexipag (Uptravi®) Phase III GRIPHON trial. The company reported that, ... Read more

December 4, 2014November 5, 2015

Experimental Pulmonary Arterial Hypertension Drug Selexipag Submitted To European Medicines Agency

News, Pulmonary Hypertension

Actelion Ltd, a biopharmaceutical company developing innovative therapeutics for orphan diseases, submitted a Marketing Authorization Application (MAA) for their lead investigational drug selexipag (Uptravi®) to the European Medicines Agency (EMA) as a new therapeutic for ... Read more